Related posts
Top Covid-19 Vaccine Stocks to Bet on the Immunization Race (Updated)Top Biotech and Pharma Stocks to Bet on Cancer Cure & ControlThis summary was created by AI, based on 5 opinions in the last 12 months.
Experts are divided in their opinions regarding GlaxoSmithKline PLC. Some believe that the current share price is fairly valued and the company has a strong vaccine business, while others feel that there are better investment opportunities elsewhere. The company is under pressure with slow growth and cost-cutting, but has a good dividend yield and strong cashflow. The key concern is the company's drug pipeline, which may require acquisitions to strengthen. Overall, there is uncertainty about the company's future direction and use of capital.
Vaccine discoveries good for business.
Does not own shares at this time.
Market for pharmaceuticals separating between strong and weak players.
Current share price fairly valued.
Big pharmas are all under pressure, growth is hard to come by and so they're cost-cutting. All have lots of free cashflow and reasonable dividend yields. He prefers JNJ.
Good business, but better opportunities out there.
Attractive dividend yield.
Not investing in business at this time.
Hard to evaluate R&D pipeline.
Would look elsewhere.
They sold their personal care business to generate a lot of capital. They're strong in vaccines, but don't have a strong pipeline of drugs. So, they need to buy other companies to make up for that. Not a high PE and pays a good dividend. The key is what they will do with their capital.
Great dividend yield of 6.3%, trades at only 10x earnings. Cheap, you can own it here. Grew vaccine business. New CEO shed some divisions, so now more of a pure pharma company, which has risks. Have to worry about pipeline constantly. JNJ, for example, is more diversified, and that's what he prefers.
It's been successfully recently, but they have to pay for their drug pipeline which looks reasonable. Not cheap, but no drug is coming to market that will do very well. So-so overall. There are better peers.
Still likes it. They spun off over-the counter and consumer pharmaceuticals like Advil and that's when shares dipped (last fall). He chose it back then to bet on Covid vaccines, but that didn't pan out. But he likes it for that spin off and you get paid a reasonable dividend.
GlaxoSmithKline PLC is a American stock, trading under the symbol GSK-N on the New York Stock Exchange (GSK). It is usually referred to as NYSE:GSK or GSK-N
In the last year, 1 stock analyst published opinions about GSK-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for GlaxoSmithKline PLC.
GlaxoSmithKline PLC was recommended as a Top Pick by on . Read the latest stock experts ratings for GlaxoSmithKline PLC.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered GlaxoSmithKline PLC In the last year. It is a trending stock that is worth watching.
On 2024-10-11, GlaxoSmithKline PLC (GSK-N) stock closed at a price of $38.83.
Buy drug stocks when there's no good news about their drug pipelines, or else you pay up when there is good news, in which case it becomes a trade, not investment.